Regarding gene mutation patterns, recent studies have determined that increased mutation in KRAS and FBXW7 have been implicated as immunosuppressive biomarkers that play a role in poor immunotherapeutic responses in CRC [46, 47]. The gene discussed is KRAS; the disease is colorectal carcinoma.